Preclinical data suggests elevating NIK levels may enhance adoptive T cell therapies
Credit: MD Anderson Cancer Center
HOUSTON — Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.
The preclinical research, published today in Nature Immunology, suggests that elevating NIK activity in T cells may be a promising strategy to enhance the effectiveness of immunotherapy, including adoptive cellular therapies and immune checkpoint blockade.
In a preclinical melanoma model, the researchers evaluated melanoma-specific T cells engineered to express higher levels of NIK. Compared to controls, these T cells displayed stronger tumor-killing abilities and improved survival, suggesting that increasing NIK activity may improve the effectiveness of adoptive T cell therapies.
“NIK is a novel regulator of T cell metabolism that works in a very unique manner. Biologically, NIK activity stabilizes the HK2 glycolytic enzyme through regulating the cellular redox pathway,” said corresponding author Shao-Cong Sun, Ph.D., professor of Immunology. “From the therapeutic point of view, we were able to improve the efficacy of adoptive T cell therapies in preclinical models by overexpressing NIK in those cells.”
T cells generally exist in a relatively quiet state with low energy demands and little cell division, Sun explained. However, upon recognizing an antigen, T cells begin expanding and activate the glycolysis metabolic pathway to meet the increased energy demands of carrying out their immune function.
This metabolic shift is closely regulated by immune checkpoint proteins, such as CTLA-4 and PD-1, which act to repress T cell metabolism. Thus, immune checkpoint inhibitors can reinvigorate T cell anti-tumor activity by boosting metabolism. In addition, T cells begin producing proteins called costimulatory molecules after they become activated, which work to stimulate metabolism and the immune response.
Knowing that the NIK protein functions downstream of many of these costimulatory molecules, the researchers sought to better understand its role in regulating T cell function. In melanoma models, NIK loss resulted in an increased tumor burden and fewer tumor-infiltrating T cells, suggesting NIK plays a crucial role in anti-tumor immunity and T cell survival.
Further experiments revealed that NIK is essential for the metabolic reprogramming in activated T cells through its control of the cellular redox system. Increased metabolism can lead to elevated levels of reactive oxygen species (ROS), which can damage the cell and stimulate protein degradation.
The researchers discovered that NIK maintains the NADPH redox system, an important antioxidant mechanism to reduce the accumulation of ROS. This in turn leads to the stabilization of the HK2 protein, a rate-limiting enzyme within the glycolysis pathway.
“Our findings suggest that without NIK, the HK2 protein is not stable, and is constantly being degraded. You need NIK to maintain HK2 levels in T cells,” Sun said. “Interestingly, we found that adding more NIK to the cells, you can further increase the levels of HK2 and make glycolysis more active.”
As a potential therapeutic application, the researchers currently are working to evaluate modified chimeric antigen receptor (CAR) T cells in the laboratory engineered to overexpress NIK. In the future, they hope to explore other therapeutic approaches, such as targeted therapies that could manipulate NIK activity in tandem with other immunotherapy approaches, including immune checkpoint inhibitors.
The research was supported by the National Institutes of Health (GM84459, 30CA016672 and IS10OD01230), the National Research Foundation of Korea (MISP 2011-0018312) and the Cancer Prevention & Research Institute of Texas (RP130397).
In addition to Sun, collaborating MD Anderson authors include Meidi Gu, Ph.D., Xiaofei Zhou, Ph.D., Le-Le Zhu, Ph.D., Zuliang Jie, Ph.D., Xiaoping Xie, Ph.D., Yaoyao Shi, Ph.D., and Xuhong Cheng all of Immunology; Jin-Young Yang, Ph.D., of Immunology and Busan National University, Busan, South Korea; Xiaofeng Zheng, and Jing Wang, Ph.D., of Bioinformatics & Computational Biology. Additional co-authors include Jee Hyung Sohn and Jae Bum Kim, Ph.D., both of Seoul National University, Seoul, Korea; Jie Yang, Ph.D., of Precision for Medicine, Houston, TX; and Hans D. Brightbill, Ph.D., of Genentech, South San Francisco, CA. A full list of disclosures can be found with the paper here.
– 30 –
Clayton R. Boldt, Ph.D.